1281 ENDOSCOPIC MOLECULAR IMAGING OF HUMAN BLADDER CANCER USING A CD47 ANTIBODY (2013)

You have accessJournal of UrologyBladder Cancer: Detection & Screening1 Apr 20131281 ENDOSCOPIC MOLECULAR IMAGING OF HUMAN BLADDER CANCER USING A CD47 ANTIBODY Ying Pan, Jens-Peter Volkmer, Jen-Jane Liu, Debashis Sahoo, Timothy Chang, Kathleen Mach, Robert Rouse, Fuad Freiha, Sanjiv Gambhir, Irving Weissman, and Joseph Liao Ying PanYing Pan Palo Alto, CA , Jens-Peter VolkmerJens-Peter Volkmer Palo Alto, CA , Jen-Jane LiuJen-Jane Liu Palo Alto, CA , Debashis SahooDebashis Sahoo Palo Alto, CA , Timothy ChangTimothy Chang Palo Alto, CA , Kathleen MachKathleen Mach Palo Alto, CA , Robert RouseRobert Rouse Palo Alto, CA , Fuad FreihaFuad Freiha Palo Alto, CA , Sanjiv GambhirSanjiv Gambhir Palo Alto, CA , Irving WeissmanIrving Weissman Palo Alto, CA , and Joseph LiaoJoseph Liao Palo Alto, CA View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2635AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Bladder cancer (BC) is primarily diagnosed with white light cystoscopy (WLC). Well-known shortcomings of WLC include difficulty in detection of high-grade flat neoplasms such as carcinoma in situ (CIS) and differentiation of malignant lesions from benign. A combination of new imaging technologies with cancer-selective molecular imaging agents is a potentially powerful strategy to improve detection of bladder cancer. Current imaging agents for clinical optical imaging systems, such as photodynamic diagnosis (PDD), lack molecular specificity. Recently, we demonstrated that the cell surface protein CD47 is overexpressed in BC. We hypothesized that CD47 could be a diagnostic target in BC for endoscopic imaging with fluorescently labeled antibody to CD47. METHODS Anti-CD47 labeled with Qdot625 was instilled intravesically through a urinary catheter into fresh intact cystectomy specimens (n=4) derived from BC patients. After incubation, excess antibody was drained, and the PDD cystoscope was inserted into the bladder for WLC and PDD. Imaging of normal-appearing, tumor, and suspicious areas was preformed. After imaging, the intact specimens were submitted for standard histopathology. Co-localization of the imaged regions with histopathology was done by cystoscopic injection of toluidine blue. RESULTS All bladders had high-grade urothelial carcinoma on pathology. Anti-CD47-Qdot625 fluorescent signal (pink) was observed in tumor area whereas normal mucosa appeared blue under PDD (Fig.1). In one bladder, anti-CD47-Qdot625 fluorescence was observed with PDD, while the same region appeared normal under WLC. Histopathologic analysis of this region demonstrated CIS. In another region, an area appeared suspicious by WLC but only blue background was observed under PDD, with histopathology showing squamous metaplasia, a benign lesion. CIS was also detected by anti-CD47-Qdot625 in another bladder, in which an inflammatory lesion appeared blue under PDD. CONCLUSIONS Using fresh surgically removed intact human bladders from BC patients, we demonstrated CD47 as a novel bladder cancer imaging target by demonstrating the feasibility of using fluorescently labeled CD47 antibody with clinical imaging systems. Molecular imaging targeting CD47 could lead to improved diagnosis and image-guided surgery for bladder cancer. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e524 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ying Pan Palo Alto, CA More articles by this author Jens-Peter Volkmer Palo Alto, CA More articles by this author Jen-Jane Liu Palo Alto, CA More articles by this author Debashis Sahoo Palo Alto, CA More articles by this author Timothy Chang Palo Alto, CA More articles by this author Kathleen Mach Palo Alto, CA More articles by this author Robert Rouse Palo Alto, CA More articles by this author Fuad Freiha Palo Alto, CA More articles by this author Sanjiv Gambhir Palo Alto, CA More articles by this author Irving Weissman Palo Alto, CA More articles by this author Joseph Liao Palo Alto, CA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...